Retrieve available abstracts of 110 articles: HTML format
Single Articles
May 2025
DICKERSON JC, Moen MT, Nielsen P Jr, Riaz F, et al Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor
2-Low Metastatic Breast Cancer.
J Clin Oncol. 2025 May 21:JCO2401960. doi: 10.1200/JCO-24-01960. PubMedAbstract available
VEENSTRA CM, Abrahamse P, Hamilton AS, Ward KC, et al Breast, Colorectal, and Pancreatic Cancer Mortality With Pathogenic Variants in
ATM, CHEK2, or PALB2.
J Clin Oncol. 2025;43:1587-1596. PubMedAbstract available
April 2025
LLOMBART-CUSSAC A, Harper-Wynne C, Perello A, Hennequin A, et al Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients
With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative
Advanced Breast Cancer: PALMIRA Trial.
J Clin Oncol. 2025 Apr 28:JCO2401865. doi: 10.1200/JCO-24-01865. PubMedAbstract available
TESCH ME, Partridge AH Can Improving Adjuvant Endocrine Therapy Persistence Improve Survival Outcomes
for Patients With Early-Stage Breast Cancer?
J Clin Oncol. 2025 Apr 16:JCO2500371. doi: 10.1200/JCO-25-00371. PubMed
TANNOCK IF, Khan QJ, Fojo T Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment
With a CDK4/6 Inhibitor.
J Clin Oncol. 2025 Apr 14:JCO2402683. doi: 10.1200/JCO-24-02683. PubMed
WINCHESTER DJ, Singh L, Edge SB, Allison KH, et al Novel Postneoadjuvant Prognostic Breast Cancer Staging System.
J Clin Oncol. 2025 Apr 11:JCO2401739. doi: 10.1200/JCO-24-01739. PubMedAbstract available
CHOONG GM, Hoskin TL, Boughey JC, Ingle JN, et al Endocrine Therapy Omission in Estrogen Receptor-Low (1%-10%) Early-Stage Breast
Cancer.
J Clin Oncol. 2025 Apr 11:JCO2402263. doi: 10.1200/JCO-24-02263. PubMedAbstract available
YAMAMOTO Y, Iwata H, Saji S, Takahashi M, et al Erratum: Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor
2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final
Overall Survival Analysis.
J Clin Oncol. 2025 Apr 11:JCO2500722. doi: 10.1200/JCO-25-00722. PubMed
PARK KU, Somerfield MR, Anne N, Brackstone M, et al Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.
J Clin Oncol. 2025 Apr 10:JCO2500099. doi: 10.1200/JCO-25-00099. PubMedAbstract available
March 2025
BARDIA A, Pistilli B, Rugo H Reply to: Assessing Clinical Utility of Datopotamab Deruxtecan Versus
Chemotherapy for Breast Cancer.
J Clin Oncol. 2025 Mar 28:JCO2402833. doi: 10.1200/JCO-24-02833. PubMed
WANG X, Ludmir EB, Wei LJ Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for
Breast Cancer.
J Clin Oncol. 2025 Mar 28:JCO2402207. doi: 10.1200/JCO-24-02207. PubMed
GROHEUX D, Vaz SC, de Geus-Oei LF, Dibble EH, et al (18)F-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography
in Staging and Restaging Patients With Breast Cancer.
J Clin Oncol. 2025 Mar 25:JCO2401945. doi: 10.1200/JCO-24-01945. PubMed
DUMAS E, Jochum F, Coussy F, Hamy AS, et al Explaining the Relationships Between Age, Endocrine Therapy Persistence, and Risk
of Recurrence in Hormone Receptor-Positive Early Breast Cancer: A Nationwide
Cohort Study.
J Clin Oncol. 2025 Mar 5:JCO2401131. doi: 10.1200/JCO.24.01131. PubMedAbstract available
MONTAGNA G, Laws A, Ferrucci M, Mrdutt MM, et al Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor
Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study.
J Clin Oncol. 2025;43:810-820. PubMedAbstract available
February 2025
LAMBERTINI M, Blondeaux E, Tomasello LM, Agostinetto E, et al Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic
Awareness of Germline BRCA Status.
J Clin Oncol. 2025 Feb 24:JCO2401334. doi: 10.1200/JCO-24-01334. PubMedAbstract available
ROBERTSON JFR, Shao Z, Noguchi S, Bondarenko I, et al Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy-Naive Women With
Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the
Phase III FALCON Trial.
J Clin Oncol. 2025 Feb 7:JCO2500116. doi: 10.1200/JCO-25-00116. PubMed
January 2025
CONFORTI F, Nekljudova V, Sala I, Ascari R, et al Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical
Trials for Early Breast Cancer.
J Clin Oncol. 2025 Jan 30:JCO2401360. doi: 10.1200/JCO-24-01360. PubMedAbstract available
YAMAMOTO Y, Iwata H, Saji S, Takahashi M, et al Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive
Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall
Survival Analysis.
J Clin Oncol. 2025 Jan 24:JCO2401673. doi: 10.1200/JCO-24-01673. PubMedAbstract available
O'MEARA TA, Tarantino P Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal
Growth Factor Receptor 2-Positive Breast Cancer in the EMERALD Study.
J Clin Oncol. 2025 Jan 22:JCO2402717. doi: 10.1200/JCO-24-02717. PubMed
MAYERHOFER C, Freedman RA, Parsons HA, Partridge AH, et al Clonal Hematopoiesis in Women With Breast Cancer.
J Clin Oncol. 2025 Jan 17:JCO2401848. doi: 10.1200/JCO-24-01848. PubMedAbstract available
SCHOUTEN AEM, Hiensch AE, Frederix GWJ, Monninkhof EM, et al Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility
Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial.
J Clin Oncol. 2025 Jan 13:JCO2401441. doi: 10.1200/JCO-24-01441. PubMedAbstract available
YAMASHITA T, Saji S, Takano T, Naito Y, et al Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for
Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast
Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
J Clin Oncol. 2025 Jan 9:JCO2401888. doi: 10.1200/JCO-24-01888. PubMedAbstract available
ROBERTSON JFR, Shao Z, Noguchi S, Bondarenko I, et al Fulvestrant Versus Anastrozole in Endocrine Therapy-Naive Women With Hormone
Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III
FALCON Trial.
J Clin Oncol. 2025 Jan 7:JCO2400994. doi: 10.1200/JCO.24.00994. PubMedAbstract available
MI L, Wei JC, Xu K, Gao J, et al Expanding the Horizon of MRONJ Research in Breast Cancer Bone Metastasis
Treatments.
J Clin Oncol. 2025 Jan 6:JCO2402205. doi: 10.1200/JCO-24-02205. PubMed
HONG RX, Xu F, Xia W, Teng YE, et al Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients
With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative
Metastatic Breast Cancer-The Phase III MECCA Trial.
J Clin Oncol. 2025 Jan 2:JCO2400938. doi: 10.1200/JCO.24.00938. PubMedAbstract available
METZGER FILHO O, Ballman K, Campbell J, Liu M, et al Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer.
J Clin Oncol. 2025 Jan 2:JCO2401875. doi: 10.1200/JCO-24-01875. PubMedAbstract available
December 2024
KALINSKY K, Bianchini G, Hamilton E, Graff SL, et al Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on
CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial.
J Clin Oncol. 2024 Dec 18:JCO2402086. doi: 10.1200/JCO-24-02086. PubMedAbstract available
ZULEY ML, Bandos AI, Duffy SW, Logue D, et al Reply to: "Breast Cancer Screening Interval: Effects of Proportions and Biases on
Benefits" and "Annual Versus Biennial Mammographic Screening".
J Clin Oncol. 2024 Dec 17:JCO2402373. doi: 10.1200/JCO-24-02373. PubMed
AUTIER P Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits.
J Clin Oncol. 2024 Dec 17:JCO2401965. doi: 10.1200/JCO-24-01965. PubMed
SPARANO JA Development and Validation of Data-Driven Estimates of Recurrence Risk and
Treatment Benefit in Early Breast Cancer.
J Clin Oncol. 2024 Dec 12:JCO2402452. doi: 10.1200/JCO-24-02452. PubMed
PUSZTAI L, Hoag JR, Albain KS, Barlow WE, et al Development and Validation of the RSClinN+ Tool to Predict Prognosis and
Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.
J Clin Oncol. 2024 Dec 2:JCO2401507. doi: 10.1200/JCO-24-01507. PubMedAbstract available
SHEN G, Ren D, Zhao F, Wang M, et al Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on
Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial.
J Clin Oncol. 2024;42:4051-4059. PubMedAbstract available
November 2024
Erratum: Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as
Monotherapy and in Combination With Targeted Therapy in Estrogen
Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced
Breast Cancer: Phase Ia/Ib EMBER Stu
J Clin Oncol. 2024 Nov 19:JCO2402470. doi: 10.1200/JCO-24-02470. PubMed
Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone
Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk
Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim
Analysis, Including 5-Yea
J Clin Oncol. 2024 Nov 19:JCO2402469. doi: 10.1200/JCO-24-02469. PubMed
AGOSTINETTO E, Caballero C, Ignatiadis M, Pop CF, et al Axillary Surgery for Patients With Residual Isolated Tumor Cells (ypN0i+) After
Neoadjuvant Systemic Therapy for Early Breast Cancer.
J Clin Oncol. 2024 Nov 12:JCO2401711. doi: 10.1200/JCO-24-01711. PubMedAbstract available
GRINDA T, Burstein HJ Anthracyclines in Early Breast Cancer: The Long Goodbye.
J Clin Oncol. 2024 Nov 5:JCO2401916. doi: 10.1200/JCO-24-01916. PubMed
October 2024
ALLEN I, Hassan H, Walburga Y, Huntley C, et al Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic
Variant Carriers.
J Clin Oncol. 2024 Oct 29:JCO2401146. doi: 10.1200/JCO.24.01146. PubMedAbstract available
WHITE AJ Growing Evidence for the Role of Air Pollution in Breast Cancer Development.
J Clin Oncol. 2024 Oct 28:JCO2401987. doi: 10.1200/JCO-24-01987. PubMed
MOSHER CE, Lee S, Addington EL, Park S, et al Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue
Interference With Functioning in Metastatic Breast Cancer.
J Clin Oncol. 2024 Oct 25:JCO2400965. doi: 10.1200/JCO.24.00965. PubMedAbstract available
TURNER N, Saura C, Aftimos P, van den Tweel E, et al Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor
2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase
III Trial (TULIP).
J Clin Oncol. 2024 Oct 23:JCO2400529. doi: 10.1200/JCO.24.00529. PubMedAbstract available
JENSEN MB, Balslev E, Knoop AS, Tuxen MK, et al Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early
Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial.
J Clin Oncol. 2024 Oct 23:JCO2400836. doi: 10.1200/JCO.24.00836. PubMedAbstract available
BARBI M, Gorman M, John VS Navigating Hormone Therapy in Postmenopausal Women: Balancing Symptom Relief With
Cancer Risk.
J Clin Oncol. 2024;42:3517-3522. PubMedAbstract available
GOEL N, Hernandez A, Cole SW Social Genomic Determinants of Health: Understanding the Molecular Pathways by
Which Neighborhood Disadvantage Affects Cancer Outcomes.
J Clin Oncol. 2024;42:3618-3627. PubMedAbstract available
BERGSTROM EN, Abbasi A, Diaz-Gay M, Galland L, et al Deep Learning Artificial Intelligence Predicts Homologous Recombination
Deficiency and Platinum Response From Histologic Slides.
J Clin Oncol. 2024;42:3550-3560. PubMedAbstract available
RASTOGI P, Bandos H, Lucas PC, van 't Veer LJ, et al Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended
Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial.
J Clin Oncol. 2024;42:3561-3569. PubMedAbstract available
THOMAS A, Mayer EL, DeMichele A, Harbeck N, et al Further Optimizing Care of Patients With Operable Hormone Receptor-Sensitive
Breast Cancer.
J Clin Oncol. 2024 Oct 9:JCO2401080. doi: 10.1200/JCO.24.01080. PubMedAbstract available
KIM DH, Theberge V, Parpia S, Kong I, et al OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once
Daily for Early Breast Cancer.
J Clin Oncol. 2024 Oct 8:JCO2400600. doi: 10.1200/JCO.24.00600. PubMedAbstract available
WU AH, Wu J, Tseng C, Stram DO, et al Air Pollution and Breast Cancer Incidence in the Multiethnic Cohort Study.
J Clin Oncol. 2024 Oct 8:JCO2400418. doi: 10.1200/JCO.24.00418. PubMedAbstract available
FUCHAO C, Jingyue S, Xiao W Denosumab Prevents Bone Loss and Microarchitectural Deterioration in
Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy.
J Clin Oncol. 2024 Oct 4:JCO2401571. doi: 10.1200/JCO-24-01571. PubMed
AL-SHAMSI HO, Abdelwahed N, Mokbel K Surveillance Systemic Imaging After Curative Intent for Breast Cancer: A Double
Standard?
J Clin Oncol. 2024 Oct 3:JCO2401186. doi: 10.1200/JCO.24.01186. PubMed
PHILLIPS KA, Kotsopoulos J, Domchek SM, Terry MB, et al Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations
in BRCA1 and BRCA2.
J Clin Oncol. 2024 Oct 2:JCO2400176. doi: 10.1200/JCO.24.00176. PubMedAbstract available
September 2024
BICKELL NA, Nattinger AB, McGinley EL, Schymura MJ, et al The Effect on Travel Distance of a Statewide Regionalization Policy for Initial
Breast Cancer Surgery.
J Clin Oncol. 2024 Sep 30:JCO2302638. doi: 10.1200/JCO.23.02638. PubMedAbstract available
YANG S Methodological Considerations for Ensuring Robustness in Exercise and Breast
Cancer Recurrence Studies.
J Clin Oncol. 2024 Sep 20:JCO2401299. doi: 10.1200/JCO-24-01299. PubMed
WARREN LEG, Bellon JR Individualized Local Recurrence Estimates for Ductal Carcinoma In Situ.
J Clin Oncol. 2024;42:3167-3169. PubMed
HAHN E, Sutradhar R, Paszat L, Nguyen L, et al Molecular Expression Assays Improve the Prediction of Local and Invasive Local
Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ.
J Clin Oncol. 2024;42:3196-3206. PubMedAbstract available
HO AY, Shiao S, Kobald SA, Chen J, et al PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab
Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor
2-Negative Breast Cancer.
J Clin Oncol. 2024 Sep 19:JCO2400003. doi: 10.1200/JCO.24.00003. PubMedAbstract available
BHARDWAJ PV, Abdou Y Navigating Treatment Pathways in Metastatic Hormone Receptor-Positive,
HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted
Therapies.
J Clin Oncol. 2024 Sep 18:JCO2401295. doi: 10.1200/JCO-24-01295. PubMedAbstract available
TORRES JM, Sodipo MO, Hopkins MF, Chandler PD, et al Racial Differences in Breast Cancer Survival Between Black and White Women
According to Tumor Subtype: A Systematic Review and Meta-Analysis.
J Clin Oncol. 2024 Sep 17:JCO2302311. doi: 10.1200/JCO.23.02311. PubMedAbstract available
LIU S, Hu R Insights and Limitations of the Study on Temporary Interruption of Endocrine
Therapy and Assisted Reproductive Technology Use in Breast Cancer Survivors.
J Clin Oncol. 2024 Sep 16:JCO2401227. doi: 10.1200/JCO-24-01227. PubMed
WEN Z, Duan S, Liu H Advancing Fertility Preservation in Patients With Breast Cancer Interrupting
Adjuvant Endocrine Therapy: Societal and Psychological Implications.
J Clin Oncol. 2024 Sep 16:JCO2401204. doi: 10.1200/JCO-24-01204. PubMed
BARDIA A, Jhaveri K, Im SA, Pernas S, et al Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated
Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor
Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
J Clin Oncol. 2024 Sep 12:JCO2400920. doi: 10.1200/JCO.24.00920. PubMedAbstract available
LOIBL S, Jassem J, Sonnenblick A, Parlier D, et al Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor
Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall
Survival Analysis With Efficacy Update.
J Clin Oncol. 2024 Sep 11:JCO2302505. doi: 10.1200/JCO.23.02505. PubMedAbstract available
KANG D, Cho J, Zhao D, Kim J, et al Scalp Cooling in Preventing Persistent Chemotherapy-Induced Alopecia: A
Randomized Controlled Trial.
J Clin Oncol. 2024;42:3115-3122. PubMedAbstract available
JHAVERI KL, Lim E, Jeselsohn R, Ma CX, et al Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in
Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal
Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER
Study.
J Clin Oncol. 2024 Sep 6:JCO2302733. doi: 10.1200/JCO.23.02733. PubMedAbstract available
JHAVERI KL, Accordino MK, Bedard PL, Cervantes A, et al Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for
PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor
2-Negative Advanced or Metastatic Breast Cancer.
J Clin Oncol. 2024 Sep 5:JCO2400110. doi: 10.1200/JCO.24.00110. PubMedAbstract available
CLASEN SC, Miller ME How We Monitor Cardiac Health in Breast Cancer Survivors.
J Clin Oncol. 2024 Sep 3:JCO2400757. doi: 10.1200/JCO.24.00757. PubMedAbstract available
August 2024
ZULEY ML, Bandos AI, Duffy SW, Logue D, et al Breast Cancer Screening Interval: Effect on Rate of Late-Stage Disease at
Diagnosis and Overall Survival.
J Clin Oncol. 2024 Aug 21:JCO2400285. doi: 10.1200/JCO.24.00285. PubMedAbstract available
BRUNNER C, Arvandi M, Marth C, Egle D, et al Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast
Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective
Study.
J Clin Oncol. 2024 Aug 20:JCO2400171. doi: 10.1200/JCO.24.00171. PubMedAbstract available
DILAWARI A, Buturla J, Osgood C, Gao X, et al US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant
for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative
Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations.
J Clin Oncol. 2024 Aug 19:JCO2400427. doi: 10.1200/JCO.24.00427. PubMedAbstract available
REEDER-HAYES KE, Jackson BE, Kuo TM, Baggett CD, et al Structural Racism and Treatment Delay Among Black and White Patients With Breast
Cancer.
J Clin Oncol. 2024 Aug 6:JCO2302483. doi: 10.1200/JCO.23.02483. PubMedAbstract available
O'BRIEN KM, Wentzensen N, Ogunsina K, Weinberg CR, et al Intimate Care Products and Incidence of Hormone-Related Cancers: A Quantitative
Bias Analysis.
J Clin Oncol. 2024;42:2645-2659. PubMedAbstract available
July 2024
PATEL BK, Carnahan MB, Northfelt D, Anderson K, et al Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in
Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.
J Clin Oncol. 2024 Jul 26:JCO2202819. doi: 10.1200/JCO.22.02819. PubMedAbstract available
KOK M, Gielen RJ, Adams S, Lennerz JK, et al Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III
Triple-Negative Breast Cancer.
J Clin Oncol. 2024 Jul 22:JCO2400372. doi: 10.1200/JCO.24.00372. PubMed
MATIKAS A, Mobus V, Greil R, Andersson A, et al Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early
Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
J Clin Oncol. 2024 Jul 17:JCO2400178. doi: 10.1200/JCO.24.00178. PubMedAbstract available
KATZ SJ, Abrahamse P, Furgal A, Hodan R, et al Genetic Counseling, Testing, and Family Communication Into Survivorship After
Diagnosis of Breast Cancer.
J Clin Oncol. 2024 Jul 15:JCO2400122. doi: 10.1200/JCO.24.00122. PubMedAbstract available
OKEYA A, Shimomura A, Kitagawa D, Shimizu C, et al Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With
ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative
Breast Cancer?
J Clin Oncol. 2024 Jul 11:JCO2400992. doi: 10.1200/JCO.24.00992. PubMed
RAMCHAND SK, Ghasem-Zadeh A, Hoermann R, White S, et al Denosumab Prevents Bone Loss and Microarchitectural Deterioration in
Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A
Randomized Controlled Trial.
J Clin Oncol. 2024 Jul 2:JCO2302309. doi: 10.1200/JCO.23.02309. PubMedAbstract available
June 2024
TARANTINO P, Tayob N, Villacampa G, Dang C, et al Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results
and Correlative Analyses From ATEMPT.
J Clin Oncol. 2024 Jun 27:JCO2302170. doi: 10.1200/JCO.23.02170. PubMedAbstract available
SCHMIDT JA, Woolpert KM, Hjorth CF, Farkas DK, et al Social Characteristics and Adherence to Adjuvant Endocrine Therapy in
Premenopausal Women With Breast Cancer.
J Clin Oncol. 2024 Jun 25:JCO2302643. doi: 10.1200/JCO.23.02643. PubMedAbstract available
KUSUMOTO M, Shimomura A, Shimizu C Shorter Duration of Trastuzumab Combined With Chemotherapy for Early Breast
Cancer.
J Clin Oncol. 2024 Jun 24:JCO2302407. doi: 10.1200/JCO.23.02407. PubMed
CORTES J, Hurvitz SA, O'Shaughnessy J, Delaloge S, et al Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus
Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor
2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5.
J Clin Oncol. 2024 Jun 18:JCO2302036. doi: 10.1200/JCO.23.02036. PubMedAbstract available
SANDOVAL JL, Franzoi MA, di Meglio A, Ferreira AR, et al Magnitude and Temporal Variations of Socioeconomic Inequalities in the Quality of
Life After Early Breast Cancer: Results From the Multicentric French CANTO
Cohort.
J Clin Oncol. 2024 Jun 18:JCO2302099. doi: 10.1200/JCO.23.02099. PubMedAbstract available
SOLDATO D, Michiels S, Havas J, Di Meglio A, et al Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast
Cancer.
J Clin Oncol. 2024 Jun 5:JCO2301959. doi: 10.1200/JCO.23.01959. PubMedAbstract available
CHAVEZ-MACGREGOR M, Miao J, Pusztai L, Goetz MP, et al Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy +/- 1 Year of
Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage
Breast Cancer.
J Clin Oncol. 2024 Jun 4:JCO2302344. doi: 10.1200/JCO.23.02344. PubMedAbstract available
BOSTANY G, Chen Y, Francisco L, Dai C, et al Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy
and Cardiovascular Risk Factors.
J Clin Oncol. 2024 Jun 4:JCO2301779. doi: 10.1200/JCO.23.01779. PubMedAbstract available
SCHNEIDER BP, Zhao F, Ballinger TJ, Garcia SF, et al ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of
Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast
Cancer.
J Clin Oncol. 2024 Jun 3:JCO2400526. doi: 10.1200/JCO.24.00526. PubMedAbstract available
CHAPMAN JW, Bayani J, SenGupta S, Bartlett JMS, et al Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and
Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast
Cancer Trial of Exemestane Versus Anastrozole.
J Clin Oncol. 2024 Jun 2:JCO2400835. doi: 10.1200/JCO.24.00835. PubMedAbstract available
RECHT A Internal Mammary Node Irradiation Debate: Case Closed? Not Yet, and Maybe Never.
J Clin Oncol. 2024;42:1871-1874. PubMedAbstract available
SORSCHER S Omission of Radiotherapy for Women With Low-Risk Invasive Cancers That Have a
Ductal Carcinoma In Situ Component.
J Clin Oncol. 2024;42:1998. PubMed
May 2024
AZIM HA JR, Niman SM, Partridge AH, Demeestere I, et al Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer
Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy.
J Clin Oncol. 2024 May 29:JCO2302292. doi: 10.1200/JCO.23.02292. PubMedAbstract available
LU YS, Bin Mohd Mahidin EI, Azim H, Eralp Y, et al Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination
chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced
breast cancer.
J Clin Oncol. 2024 May 21:JCO2400144. doi: 10.1200/JCO.24.00144. PubMedAbstract available
SANTHOSH A, Sharma A, Bakhshi S, Kumar A, et al Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome:
A Double-Blind Randomized Controlled Trial.
J Clin Oncol. 2024;42:1821-1829. PubMedAbstract available
FREEDMAN RA, Caswell-Jin JL, Hassett M, Somerfield MR, et al Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast
Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid
Recommendation Update.
J Clin Oncol. 2024 May 20:JCO2400886. doi: 10.1200/JCO.24.00886. PubMedAbstract available
RAPP SR, Dressler EV, Brown WM, Wade JL 3rd, et al Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for
Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant
Chemotherapy (WF-97116).
J Clin Oncol. 2024 May 6:JCO2301100. doi: 10.1200/JCO.23.01100. PubMedAbstract available
April 2024
Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone
Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk
Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim
Analysis, Including 5-Yea
J Clin Oncol. 2024 Apr 30:JCO2400711. doi: 10.1200/JCO.24.00711. PubMed
BARDIA A, Krop IE, Kogawa T, Juric D, et al Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative
Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
J Clin Oncol. 2024 Apr 23:JCO2301909. doi: 10.1200/JCO.23.01909. PubMedAbstract available
RIOS-HOYO A, Cobain E, Huppert LA, Beitsch PD, et al Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human
Epidermal Growth Factor 2-Negative Breast Cancer.
J Clin Oncol. 2024 Apr 9:JCO2302614. doi: 10.1200/JCO.23.02614. PubMed
VALENZA C, Trapani D, Loibl S, Chia SKL, et al Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer
Achieving Pathologic Complete Response.
J Clin Oncol. 2024 Apr 3:JCO2301935. doi: 10.1200/JCO.23.01935. PubMedAbstract available
MUTTER RW, Chauhan C, Goetz MP, Wright JL, et al Revisiting Combined Modality Therapy in Older Patients With Luminal Breast Cancer
Through the Patient Lens.
J Clin Oncol. 2024 Apr 2:JCO2302289. doi: 10.1200/JCO.23.02289. PubMed
March 2024
MARTIN M, Lim E, Chavez-MacGregor M, Bardia A, et al Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated
Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast
Cancer Study.
J Clin Oncol. 2024 Mar 27:JCO2301500. doi: 10.1200/JCO.23.01500. PubMedAbstract available
MAYER EL, Ren Y, Wagle N, Mahtani R, et al PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After
Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for
Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative
Metastatic Bre
J Clin Oncol. 2024 Mar 21:JCO2301940. doi: 10.1200/JCO.23.01940. PubMedAbstract available
SALTBAEK L, Bidstrup PE, Karlsen RV, Hoeg BL, et al Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After
Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial.
J Clin Oncol. 2024 Mar 18:JCO2301447. doi: 10.1200/JCO.23.01447. PubMedAbstract available
MANN GB, Rose AK, Zdenkowski N What About This IDEA: The PROSPECT That Occult Malignant Lesions May Explain
Local Recurrences in Very Early Breast Cancer?
J Clin Oncol. 2024 Mar 15:JCO2302729. doi: 10.1200/JCO.23.02729. PubMed
BURSTEIN HJ, DeMichele A, Fallowfield L, Somerfield MR, et al Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal
Growth Factor Receptor 2-Negative Metastatic Breast
Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
J Clin Oncol. 2024 Mar 13:JCO2400248. doi: 10.1200/JCO.24.00248. PubMedAbstract available
RADFORD J Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in
Curable Cancers.
J Clin Oncol. 2024 Mar 13:JCO2302763. doi: 10.1200/JCO.23.02763. PubMed
February 2024
MARS N, Kerminen S, Tamlander M, Pirinen M, et al Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in
Women.
J Clin Oncol. 2024 Feb 29:JCO2300295. doi: 10.1200/JCO.23.00295. PubMedAbstract available
BARDIA A, Rugo HS, Tolaney SM, Loirat D, et al Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic
Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal
Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
J Clin Oncol. 2024 Feb 29:JCO2301409. doi: 10.1200/JCO.23.01409. PubMedAbstract available
MAXWELL KN, Domchek SM Toward Application of Polygenic Risk Scores to Both Enhance and Deintensify
Breast Cancer Screening.
J Clin Oncol. 2024 Feb 29:JCO2400029. doi: 10.1200/JCO.24.00029. PubMed
Erratum: Pathologic Exploration of the Axillary Soft Tissue Microenvironment and
Its Impact on Axillary Management and Breast Cancer Outcomes.
J Clin Oncol. 2024 Feb 23:JCO2400317. doi: 10.1200/JCO.24.00317. PubMed
WORIAX HE, Thomas SM, Plichta JK, Rosenberger LH, et al Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in
Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant
Chemotherapy.
J Clin Oncol. 2024 Feb 23:JCO2301199. doi: 10.1200/JCO.23.01199. PubMedAbstract available